Modality
siRNA
MOA
JAK1i
Target
EGFR
Pathway
Angiogenesis
RBASMCL
Development Pipeline
Preclinical
~May 2021
→ ~Aug 2022
Phase 1
~Nov 2022
→ ~Feb 2024
Phase 2
May 2024
→ Jul 2027
Phase 2Current
NCT06240550
713 pts·RB
2025-05→2025-06·Recruiting
NCT06575938
168 pts·MCL
2024-05→2027-07·Recruiting
881 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-06-1310mo agoPh2 Data· RB
2026-10-177mo awayConference· MCL
2027-07-241.3y awayPh2 Data· MCL
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2
Recruit…
P2
Recruit…
Catalysts
Ph2 Data
2025-06-13 · 10mo ago
RB
Conference
2026-10-17 · 7mo away
MCL
Ph2 Data
2027-07-24 · 1.3y away
MCL
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06240550 | Phase 2 | RB | Recruiting | 713 | UPCR |
| NCT06575938 | Phase 2 | MCL | Recruiting | 168 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα | |
| RCU-2903 | Arcus Bio | NDA/BLA | EGFR |